U.S. Markets open in 8 hrs 13 mins

Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugen’s BAY 1905254 Efficacy in Cancer Immunotherapy

Stock Monitor: Affimed Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on Compugen Ltd (NASDAQ: CGEN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CGEN as the Company's latest news hit the wire. On April 17, 2018, the Company announced that preclinical data presented by Bayer AG at the Annual Meeting of the American Association of Cancer Research (AACR) held April 14-18, 2018, in Chicago, Illinois, highlights the efficacy of BAY 1905254 (formerly the CGEN-15001T program) in cancer immunotherapy. Bayer plans to advance the program into first-in-human trials in 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Affimed N.V. (NASDAQ: AFMD), which also belongs to the Healthcare sector as the Company Compugen. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=AFMD

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Compugen most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CGEN

BAY 1905254 Exhibits Anti-Tumor Activity as a Monotherapy in Various Mouse Models

The data was highlighted in a Bayer poster presentation titled "Discovery and preclinical characterization of BAY 1905254" a novel immune checkpoint inhibitor for cancer immunotherapy targeting the immunoglobulin-like domain containing receptor-2 (ILDR2). The data demonstrated that BAY 1905254 exhibits anti-tumor activity as a monotherapy in various mouse models and was also shown to have additive/synergistic anti-tumor effects in combination with other cancer therapy approaches, indicating the possibility for multiple combination approaches for use in cancer immunotherapy.

ILDR2 is a Completely New Immune Checkpoint that Compugen has Discovered through its Computational Discovery Capabilities

Anat Cohen-Dayag, PhD, President and CEO of Compugen, stated that this is an exciting time for Compugen as it has become a clinical stage drug discovery and development company with two immuno-oncology programs advancing into the clinic this year, an internally developed program targeting PVRIG and an antibody targeting ILDR2 developed in collaboration with Bayer.

Anat added that ILDR2 is a completely new immune checkpoint that the Company has discovered through its computational discovery capabilities. This immune checkpoint, together with the discovery of TIGIT and PVRIG, clearly demonstrate the power and value of Compugen's predictive discovery capabilities in the discovery of new drug targets and pathways, enabling the development of first-in-class product opportunities.

Compugen-Bayer Collaboration

In August 2013, Compugen entered into a collaboration and license agreement with Bayer for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen-discovered immune checkpoint regulators, BAY 1905254 (formerly CGEN- 15001T) and CGEN-15022. Under the terms of the agreement, Bayer and Compugen have jointly pursued a preclinical research program. Bayer has taken full control over further development and have worldwide commercialization rights for potential cancer therapeutics for one of the programs, BAY 1905254, for which preclinical stage milestones have been achieved and preclinical development is on track. In July 2016, all rights to CGEN-15022 were returned to Compugen.

About BAY 1905254

BAY 1905254, Compugen's lead program for autoimmune diseases, is a first-in-class therapeutic antibody candidate targeting ILDR2, with the potential to restore immune tolerance and re-establish immune homeostasis, thus potentially offering patients a durable therapeutic response and a safer treatment profile. BAY 1905254 has a broad preclinical data package supporting its unique mode-of-action and therapeutic potential. It was previously shown to be effective in treating several autoimmune diseases in animal models, including models of multiple sclerosis, rheumatoid arthritis, type-1 diabetes, and psoriasis.

About Compugen Ltd

Founded in 1993 and headquartered in Holon, Israel, Compugen is a leading drug discovery company with a unique, broadly applicable, predictive discovery infrastructure, which is advancing a therapeutic pipeline consisting mainly of early-stage immuno-oncology programs, aimed at harnessing the immune system to eradicate cancer.

Stock Performance Snapshot

April 18, 2018 - At Wednesday's closing bell, Compugen's stock rose 2.35%, ending the trading session at $4.35.

Volume traded for the day: 162.26 thousand shares.

Stock performance in the last month – up 3.57%; previous three-month period – up 58.18%; past twelve-month period – up 6.10%; and year-to-date - up 74.00%

After yesterday's close, Compugen's market cap was at $223.76 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was flat at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors